score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1879	346.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.E726K	0.2857	343.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				EZH2 p.E726K (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat11		
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G477D	0.2955	264.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.G477D (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S1385F	0.1463	670.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0				MET p.S1385F (Missense)	0.0	MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.2067	179.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.S241F (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S970F	0.10400000000000001	298.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SETBP1 p.S970F (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat11		
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.S526F	0.2047	127.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC1 p.S526F (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1425S	0.0913	219.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				ARID1A p.P1425S (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P2137L	0.2643	473.0	0.0	0.0																Investigate Actionability	0.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				PRPF8 p.P2137L (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.G645C	0.1714	35.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				ASXL1 p.G645C (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.A307T	0.06	150.0	0.0	0.0																					0				SLC45A3 p.A307T (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1419F	0.0996	231.0	0.0	0.0																					0				ROS1 p.S1419F (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S370T	0.1099	191.0	0.0	0.0																					0				ROS1 p.S370T (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E94K	0.0808	198.0	0.0	0.0																					0				ROS1 p.E94K (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P255S	0.0853	129.0	0.0	0.0																					0				LIMK2 p.P255S (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.P255L	0.0853	129.0	0.0	0.0																					0				LIMK2 p.P255L (Missense)		MEL-IPI_Pat11	MEL-IPI_Pat11-Tumor-SM-4DK17	MEL-IPI_Pat11-Normal-SM-4NFUD
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat11		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.883																									0				COSMIC Signature (version 2) 7 (88%)		MEL-IPI_Pat11		
